TriangleDISEASE & TREATMENT SETTING
OPDIVO: Urothelial carcinoma (adjuvant) after prior therapy
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
1.10 Urothelial Carcinoma OPDIVO is indicated for the adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC [see Clinical Studies (14.10) ] .
Broader topic: Urothelial Carcinoma
- Source population
- Not part of this definition
- Disease extent
- Not part of this definition
- Treatment line
- adjuvant
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- prior therapy
- class
- after undergoing radical resection of UC [see Clinical Studies (14
- status
- required
- derivation status
- source-attested
- derivation note
- Scoped from the FDA approved indication for OPDIVO (product label). Only dimensions stated in that wording are part of this definition.
- source wording
- 1.10 Urothelial Carcinoma OPDIVO is indicated for the adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC [see Clinical Studies (14.10) ] .
Study evidence for this setting
No linked study matches these filters. This is a source-coverage gap, not evidence that there are no treatment options.
Source relationships and population-mapping limitations
- bindings
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice